lifestyle.wordsjournal.com

Author: LB Pharmaceuticals Inc

LB Pharmaceuticals Announces Publication in JAMA Psychiatry of Results from Phase 2 NOVA-1 Trial of LB-102 in Schizophrenia

April 22, 2026
LB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial Highlighting LB-102’s Potential Impact on Cognitive Performance at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)

March 27, 2026
LB Pharmaceuticals Initiates Pivotal Phase 3 Trial (NOVA-2) for LB-102 in Patients with Schizophrenia

March 25, 2026
LB Pharmaceuticals Appoints R&D Biotech Executive Robert Lenz, M.D., Ph.D. to Board of Directors

March 9, 2026
LB Pharmaceuticals to Participate in Upcoming March Investor Events

March 4, 2026
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

February 11, 2026
LB Pharmaceuticals Announces $100.0 Million Private Placement

February 10, 2026
LB Pharmaceuticals Initiates Phase 2 ILLUMINATE-1 Trial in Bipolar Depression, Expanding LB-102 Development Program

January 26, 2026
LB Pharmaceuticals Appoints Minako Pazdera, J.D., Ph.D. as General Counsel

January 21, 2026